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1. Abbreviations 
ACh Acetylcholine 
AChE Acetylcholinesterase 
AIC Akaike’s information criterion 
ATCh Acetylthiocholine 
AUC Area under the concentration-time curve 
BChE Butyrylcholinesterase 
Bmax Binding capacity 
Cb Bound concentration 
Cf Unbound concentration 
CLinf,app Initial uptake clearance 
CLtot Total body clearance 
FD Functional dyspepsia 
fu Unbound fraction 
GFR Glomerular filtration rate 
GI Gastrointestinal 
IC50 Half maximal inhibitory concentrations 
Kd Dissociation constant 
Kp Tissue-to-plasma concentration ratio 
LC-MS/MS Liquid chromatography-mass spectrometry/mass spectrometry 
Loglik Maximized log-likelihood function 
PBPK Physiologically based pharmacokinetic 
PBPK/PD Physiologically based pharmacokinetic and pharmacodynamic 
PD Pharmacodynamic 
PK Pharmacokinetic 
Qt Blood flow rate 
PS Permeability surface area product 
Rbp Blood-to-plasma concentration ratio 
RNA Ribonucleic acid 
S.D. Standard deviation 
S.E. Standard error 
UGT Uridine 5’-diphosphate glucuronosyltransferase 
Vd Distribution volume 
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2. General introduction 
Functional dyspepsia (FD) is a common gastrointestinal disorder defined as 
symptom-based conditions in the absence of organic disease [1,2,3]. Symptoms are 
categorized as postprandial distress and epigastric pain syndromes, which are associated 
with impaired gastric accommodation and emptying [4,5]. Gastric accommodation and 
emptying are induced by coordinating motility of gastric fundus, body and antrum, which 
are regulated by complex nervous systems including cholinergic neurons projected from 
dorsal motor nucleus of the vagus to the stomach [6,7]. The cholinergic system is 
regulated by factors such as acetylcholine (ACh). ACh is released from presynaptic 
neurons into the synaptic cleft, where it then binds to ACh receptors and either affects 
gastric motility or is inactivated by acetylcholinesterase (AChE). This relationship 
suggests that gastric motility might be regulated via the inhibition of AChE activity and 
that AChE inhibitors might effectively treat patients with FD [8,9]. 
Acotiamide is an AChE inhibitor and first-in-class drug for the treatment of FD 
[10,11,12,13,14]. Although some clinical studies have suggested that proton pump 
inhibitors (e.g., omeprazole) and prokinetics (e.g., itopride or mosapride) are effective, no 
product except for acotiamide has gotten marketing approval for the treatment of patients 
with FD [10]. Clinical studies have shown that acotiamide enhances the gastric 
accommodation reflex and gastric emptying rate [11] and improves meal-related 
symptoms such as postprandial fullness, upper abdominal bloating and early satiation in 
patients of FD [12]. In rats and dogs, acotiamide enhances gastric emptying and also 
increases gastrointestinal (GI) motility [15,16], and is expected to inhibit AChE in gastric 
muscle. Acotiamide is also anticipated to be effective by the distribution from blood to the 
stomach because acotiamide stimulated gastric motility after both intravenous and oral 
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administration to dogs [15]. On the other hand some experiments were performed after the 
subcutaneous administration of acotiamide to rats to investigate the enhancement of 
gastric motility by acotiamide in detail because the exposure after the subcutaneous 
administration of acotiamide is higher than that after the oral administration of acotiamide 
in rats [17]. These experiments suggested that acotiamide in the stomach tissue might be 
effective for enhancement of gastric motility as the whole stomach tissue concentration of 
acotiamide was higher than the half maximal inhibitory concentrations (IC50) for AChE 
after the subcutaneous administration of acotiamide to rats although further studies are 
needed to determine the concentration of acotiamide around target of its action like AChE 
[17]. Since the stomach tissue concentration of acotiamide could be important for the 
pharmacological action of acotiamide, understanding the distribution of acotiamide to 
target organ is of importance for evaluating the potential of this drug for treating FD. 
  AChE inhibitors are also used for the treatment of myasthenia gravis as ACh is required 
for the contraction of muscle fibers [18]. Therefore, the potential adverse effect of 
acotiamide on skeletal muscle would be an undesirable outcome during the treatment of 
FD. As cholinergic nerves develop not only in the GI tract, but also in brain tissue, drugs 
inhibiting AChE would also act on the brain if they passed through the blood-brain barrier. 
Since distribution into these tissues might cause adverse effects, such as muscle twitching 
and cholinergic crisis, investigating the distribution of acotiamide to nontarget organs is of 
importance for estimating the possibility of adverse effects of this drug. 
Distribution of drugs to stomach is determined by its physicochemical properties such 
as solubility, partition coefficient and ionization constant, tissue binding to cellular 
components, and transport. Especially, pharmacokinetic data related to the transport of 
drugs from lumen or vessels to the stomach is of considerable interest to gastroenterology 
researchers. A recent report has provided valuable information for the transfer of 
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amoxicillin in vivo from blood to the stomach in rats, although the main aim of the study 
was not to investigate the distribution mechanism of this antibiotic [19]. The 
inhomogeneous mucosal distribution of amoxicillin, whose concentrations in the glandular 
stomach mucosa were higher than those in the forestomach mucosa, may imply a specific 
distribution mechanism of the drug. Although in vitro uptake studies with isolated cells are 
a useful technique to identify the possible molecular mechanisms involved in the 
distribution of a target drug, it is impossible to eliminate the introduction of artifacts or 
determine if the test compound is transported via basolateral membranes using such in 
vitro approaches. Therefore, further in vivo studies using a pharmacokinetic approach are 
needed for investigating the distribution of acotiamide to the stomach. 
Here, the purposes of the present studies were to examine whether the concentration of 
acotiamide at the site of action is sufficient to inhibit AChE in chapter 1, to reveal the 
mechanism of distribution of acotiamide to stomach in chapter 2, and to elucidate a role of 
distribution of acotiamide in the pharmacokinetics and pharmacodynamics of acotiamide 
in chapter 3. 
 
Fig. 1.  Structure of acotiamide hydrochloride. 
 
*
∙ HCl ∙ 3H2O
* donates carbon-14
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3. Distribution of acotiamide, an orally active acetylcholinesterase inhibitor, into 
the myenteric plexus of rat and dog stomachs 
3.1. Introduction 
The pharmacological and therapeutic effects of acotiamide are thought to be derived 
from its inhibitory effects on acetylcholinesterase (AChE) which results in the potentiation 
cholinergic neurons [15]. In fact, an in vitro animal experiment showed that acotiamide 
enhanced acetylcholine (ACh)-induced but not carbachol (not hydrolyzed by 
AChE)-induced contraction of isolated gastric antrum strips of guinea pig [15]. In addition, 
an in vivo animal experiment showed that acotiamide enhanced gastric body contractions 
induced by electrical stimulation of the vagus nerve in rats, which were completely 
abolished by classical antagonist of ACh receptors [17].  
Acotiamide inhibits AChE with half maximal inhibitory concentrations (IC50) of 3.0, 
2.3 and 1.2 μM for human recombinant, and rat and canine gastric AChEs, respectively 
[15,17]. These values are much larger than those of classical inhibitors of AChE, such as 
neostigmine, however, acotiamide is concentrated into the stomach tissue by 
carrier-mediated uptake processes, which may account for the selective action of 
acotiamide for gastric smooth muscle but not for skeletal muscle and central nervous 
system in rats [20].  
Myenteric plexus is a mesh-like system of neurons which provide major motor 
innervation to the gastrointestinal muscles [21]. Therefore, main target of acotiamide 
action is thought to be AChE localized around the cholinergic nerve terminals in the 
myenteric plexus which is located in the muscular layer of the stomach. However, whether 
sufficient concentrations of acotiamide are attained in the myenteric plexus of the stomach 
to inhibit AChE, has not been confirmed in any species yet, although the total 
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concentrations of acotiamide in the homogenate of rat stomach after in vivo administration 
were reported to be higher than in vitro IC50 value of acotiamide estimated from rat gastric 
AChE [17].  
The aim of the present study was to examine the distribution of acotiamide into the 
myenteric plexus of the stomach after [
14
C]acotiamide dose enough to exhibit 
pharmacological action, using macro- and micro-autoradiographs, and to estimate whether 
the sufficient concentration of acotiamide is attained in the myenteric plexus of the 
stomach, a putative site of acotiamide action, to inhibit AChE in rat and dog stomachs.  
3.2. Materials and Methods 
3.2.1. Chemicals 
N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]t
hiazole-4-carboxamide monohydrochloride trihydrate (acotiamide hydrochloride, 
Z-338/YM443) was synthesized in the central research laboratories of Zeria 
Pharmaceutical Co., Ltd. (Saitama, Japan). [
14
C]Acotiamide (2.26 GBq/mmol) was 
synthesized by GE Healthcare UK Ltd. (Buckinghamshire, England). All other chemicals 
were of reagent grade. 
3.2.2. Animals 
Male Sprague-Dawley rats aged six to seven weeks were obtained from Charles 
River Japan, Inc. (Kanagawa, Japan) and housed under standard controlled environmental 
conditions at 23 ± 3°C and 55 ± 20% humidity with a 12-h light/dark cycle, and food 
(CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan or CE-2; CLEA Japan Inc., Tokyo, Japan) 
and water available ad libitum. Rats were allowed to acclimate to laboratory conditions for 
at least one week prior to experiments. 
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Male beagle dogs were obtained from Oriental Yeast Co., Ltd. (Tokyo, Japan) or the 
Institute for Animal Reproduction (Ibaraki, Japan) and housed individually in 
experimental cages where they were acclimated for at least 12 days before entry to the 
study. Laboratory chow (NVE-10, Nihon Pet Food K.K., Tokyo, Japan; or DS-A, Oriental 
Yeast Co., Ltd.) was provided once daily and water was given ad libitum. Animals were 
housed under standard controlled environmental conditions at 22 ± 3°C and 50 ± 20% 
humidity with a 12-h light/dark cycle. 
All animal experiments were approved by the Animal Care and Use Committee of 
the Central Research Laboratories of Zeria Pharmaceutical Co., Ltd., Animal Ethical 
Committee, Tsukuba Laboratories, Nemoto Science Co., Ltd. (Ibaraki, Japan) and the 
Institutional Animal Care and Use Committee of Shin Nippon Biomedical Laboratories, 
Ltd. (Wakayama, Japan). 
3.2.3. AChE staining of rat stomach 
Rats were exsanguinated via the abdominal aorta under anesthesia with diethyl ether 
and the stomach was excised, washed with saline, ligated at the pylorus, filled with OCT 
compound through the cardia, ligated at the cardia. Stomach was embedded with OCT 
compound and frozen in a bath of isopentane and dry ice. Embedded stomach was cut into 
6-μm-thick sections using a cryomacrocut CM1900, and immersed in 3 mM copper 
sulfate/0.05 mM potassium ferricyanide solution containing acetylthiocholine iodide at 
37°C for 90 min. After rinsing in distilled water, sections were immersed in Mayer’s 
hematoxylin for 10 min and then washed with running tap water, dehydrated in ethyl 
alcohol, and immersed in xylene. 
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3.2.4. AChE staining of dog stomach 
Dogs were euthanized by intravenous administration of sodium pentobarbital and 
supersaturated potassium chloride solutions.  Stomach was immediately excised, and 
divided into 2 pieces along the greater curvature. The pieces were rinsed with 
physiological saline and divided into approximately 1.5 cm × 1.5 cm sections and frozen 
in liquid nitrogen. Sections were embedded with an OCT compound and frozen in hexane 
and dry ice. The frozen serial sections were prepared as 8-μm sections using a 
cryomacrocut CM1900. The sections were immersed as described in AChE staining of 
stomachs of rats.  
3.2.5. Macro-autoradiography of rat stomach 
As any pharmacological effects haven’t been reported after oral administration of 
acotiamide to rats although acotiamide is orally administered for the treatment of FD, rats 
were subcutaneously administered with [
14
C]acotiamide (30 mg and 20.6 MBq/kg). These 
dose and route of acotiamide administration were reported to increase the gastric motility 
index significantly until 90 min after the administration to rats [17]. Rats were 
exsanguinated via the abdominal aorta under anesthesia with diethyl ether, and the 
stomach was excised at 30 min after the administration of acotiamide. The excised 
stomach was washed with saline, ligated at the pylorus, filled with 2% CMC-Na through 
the cardia, ligated at the cardia, embedded with 2% CMC-Na and frozen in a hexane/dry 
ice bath. The embedded stomach was cut into 40-μm-thick sections using a cryomicrotome 
CM3600 (Leica Microsystems GmbH, Wetzlar, Germany). Sections were exposed by 
contact with an Imaging-Plate BAS-III2040 (Fuji Photo Film, Tokyo, Japan) in a shield 
box for 16 h. After exposure, the Imaging-Plate was analyzed with a Bio-Imaging 
Analyzer BAS-2000 (Fuji Photo Film, Tokyo, Japan) to obtain 
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macro-autoradioluminograms and measure radioactivities in the tissues. The concentration 
of the radioactivity in the tissue was quantified by the absolute calibration method 
[22,23,24,25]. The calibration curve through the origin (Y=aX ) was prepared based on the 
mean value of the intensity of luminescence ( PSL-BG/mm
2
 ) of the blood simultaneously 
collected when stomach was removed and blood concentration of acotiamide determined 
by a liquid scintillation analyzer LSC-6100 (Aloka, Tokyo, Japan). The background (BG) 
value was calculated as the mean value of the intensity of luminescence in three positions 
on the rim of the section. The lower limit of quantification was defined as twice the BG 
value. Tissue concentration of acotiamide (mean ± standard deviation) was expressed as 
μM based on the assumption that tissue specific gravity equals 1 g/ml. 
3.2.6. Macro-autoradiography of dog stomach 
Dogs were anaesthetized with medetomidine and isoflurane, and subjected to 
abdominal incision. A catheter was inserted into the duodenum from an incision and 
[
14
C]acotiamide (30 mg and 1 MBq/kg) was administered. These dose and route of 
acotiamide administration were reported to increase the gastric motility index significantly 
at least until 30 min after the administration to dogs [26]. Dogs were euthanized by 
intravenous administration of 64.8 mg/ml sodium pentobarbital solution (2 ml/kg) at 
30 min after dosing. The cardia of the stomach was tied with a silk suture and the stomach 
was promptly enucleated. The excised stomach was washed with saline and ligated at the 
pylorus. The stomach was embedded with 5% CMC-Na and frozen in a bath of hexane 
and dry ice. The embedded stomach was cut into 30-μm-thick sections using a 
cryomicrotome CM3600, which were exposed by contact with an Imaging-Plate 
BAS-MS2040 in a shield box for 16 h. After exposure, the Imaging Plate was analyzed 
with the Bio-Imaging Analyzer BAS-2500 (Fuji Photo Film, Tokyo, Japan) to obtain 
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macro-autoradioluminograms and measure radioactivities in the tissues. The concentration 
of the radioactivity in the tissue was quantified by the absolute calibration method as 
described in macro-autoradiography of rat stomach. Tissue concentration of acotiamide 
(mean ± standard deviation) was expressed as μM based on the assumption that tissue 
specific gravity equals 1 g/ml. 
3.2.7. Nissl Staining and Micro-autoradiography of rat stomach 
Rats were treated with [
14
C]acotiamide and the stomach was excised as described in 
macro-autoradiography of rat stomach. Excised stomach was washed with saline, 
immersed in 10% formalin, and then placed in gum sucrose solution. Once complete 
submersion was confirmed, stomach was ligated at the pylorus, filled with OCT 
compound through the cardia, ligated at the cardia, embedded with an OCT compound and 
frozen in liquid nitrogen. Serial sections of 6-µm-thick were obtained with a cryomacrocut 
CM1900 (Leica Microsystems GmbH) and attached onto MAS-coated glass slides 
(Matsunami Trading Co., Ltd., Osaka, Japan) covered with emulsion for the 
micro-autography and without emulsion for Nissl staining. For Nissl staining, sections 
were dehydrated in ethanol, rehydrated in distilled water and submerged in 0.1% cresyl 
violet solution for approximately 30 min until the desired depth of staining was achieved. 
Sections were dehydrated in ethanol, immersed in xylene, and covered with a coverslip. 
For the micro-autoradiography, sections were set in a slide glass case and dried completely, 
then exposed in a refrigerator at 4°C for 2 weeks. Sections were developed, subjected to 
hematoxylin and eosin staining, and finally covered with a coverslip. 
3.3. Results and Discussion 
Although the localization of AChE in the muscular layer of the stomach has been 
reported for humans [27], little information is available on the experimental animals. 
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Therefore, we studied the localization of AChE in the muscular layer of rat and dog 
stomachs using AChE staining. As shown in the Fig. 1-1, AChE-activity was detected 
around the nerve cells in the muscular layer of the rat stomach, which were located 
between the circular and longitudinal muscles, indicating that the nerve cells are 
components of the myenteric plexus. Similarly, AChE-activity was also found in the 
ganglia of the myenteric plexus of the dog stomach (Fig. 1-2). These findings are 
consistent with those of humans [27], and suggest that major target of acotiamide action in 
rats and dogs is AChE in the ganglia of myenteric plexus located in the muscular layer of 
the stomach.  
 
Fig. 1-1.  Photomicrograph of AChE activity staining for the muscular layer of rat stomach. 
The stomach was embedded with OCT compound. Embedded stomach was cut into 6-μm-thick 
sections and immersed in 3 mM copper sulfate/0.05 mM potassium ferricyanide solution containing 
Nerve cells
L
C
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acetylthiocholine iodide at 37°C for 90 min. Then, sections were immersed in Mayer’s hematoxylin, 
dehydrated in ethyl alcohol, and immersed in xylene. Scale bar represents 20 μm. Arrow in 
photomicrograph indicates nerve cells, and brownish site indicates AChE activity staining located 
between the circular (C) and longitudinal (L) muscles. 
 
Fig. 1-2.  Photomicrograph of AChE activity staining for the muscular layer of dog stomach. 
The stomach was embedded with OCT compound. Embedded stomach was cut into 8-μm sections and 
immersed as described in AChE staining of rat stomach. Scale bar represents 100 μm. Arrow in 
photomicrograph indicates the ganglia, and brownish site indicates AChE activity staining. 
 
Macro-autoradiograms of rat and dog stomachs after the administration of 
[
14
C]acotiamide are shown in Fig. 1-3 and Fig. 1-4, respectively. The autoradiograms of 
rat and dog stomachs showed no marked difference of the radioactivity between the 
stomach sections. The mean concentration of acotiamide in the stomach of rats estimated 
from the radioactivity was 27.9±10.4 μM (n=3), which was 12 times higher than IC50 of 
acotiamide (2.3 μM) estimated from an in vitro experiment using rat gastric AChE [17]. 
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Although mucosal and muscular layers were not distinguishable in the rat stomach (Fig. 
1-3), they were distinguished in the dog stomach (Fig. 1-4). The mean concentration of 
radioactivity in the muscular layer of the dog stomach (1.41±0.18 μM, n=3) was 
approximately two-times lower than that of mucosal layer (3.24±0.66 μM, n=3), however, 
it was approximately 1.2 times higher than IC50 of acotiamide (1.2 μM) estimated from an 
in vitro experiment using dog gastric AChE [15].  
 
Fig. 1-3.  Macro-autoradiogram of rat stomach. 
Thirty mg/kg of [
14
C]acotiamide (20.6 MBq/kg) were administered subcutaneously to rats and the 
stomach was excised at 30 min after the administration. The excised stomach was embedded with 2% 
CMC-Na, sliced into 40-μm-thick sections, exposed to imaging plate for 16 h and analyzed with 
imaging analyzer. 
  
Forestomach
Gastric body
Gastric antrum
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Fig. 1-4.  Macro-autoradiogram of dog stomach. 
Thirty mg/kg of [
14
C]acotiamide (1 MBq/kg) were administered intra-duodenally to dogs and the 
stomach was excised at 30 min after the administration. The stomach was embedded with 5% CMC-Na, 
sliced into 30-μm-thick sections, exposed to imaging plate for 16 h and analyzed with imaging 
analyzer. 
 
Nissl stained and micro-autoradiographic images of the muscular layer in the rat 
stomach are shown in Fig. 1-5A and B, respectively. As shown in the Fig. 1-5A, Nissl 
stain clearly visualized nerve cells of myenteric plexus in the muscular layers of rat 
stomach. Micro-autoradiogram also showed that the radioactivity distributed 
homogenously in the muscular layer (the radioactivity was detected as black-silver grains) 
and distribution of the radioactivity was not apparently different between the surrounding 
of nerve cells and other regions of muscular layer of rat stomach (Fig. 1-5B). The results 
suggest that the concentration of radioactivity around the ganglion of the myenteric plexus 
is similar to that in the muscular layer of the rat stomach. However, in the case of rats, the 
result of the macro-autoradiography showed that the muscular layer could not be 
Gastric body
Gastric antrum
Gastric fundus
Muscular layer
Mucosa
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distinguished from mucosal layer (Fig. 1-3) probably due to the thinness of the rat gastric 
wall. Thus, it may be impossible to estimate the concentrations of radioactivity directly 
from the macro-autoradiography. Nonetheless, assuming the difference in the 
concentrations of acotiamide between muscular and mucosal layers found in dog stomach 
is similar to that in rat stomach, the concentrations of radioactivity in the muscular layer of 
rat stomach are estimated to be 8.5 μM, which was still much higher than IC50 of 
acotiamide (2.3 μM) estimated from an in vitro experiment using rat gastric AChE [17]. 
On the other hand, in the case of dogs, the concentrations of radioactivity in the muscular 
layer could be directly estimated from macro-autoradiography, therefore the 
concentrations of radioactivity around the ganglion of the myenteric plexus would be 
identical to those estimated from macro-autoradiography (1.41 μM). The concentration 
was higher than IC50 of acotiamide for dog gastric AChE (1.2 μM) [15], as described 
above. These findings suggest that adequate amount of acotiamide could distribute into the 
ganglion of the myenteric plexus of the stomach to inhibit AChE in both of the rat and dog 
stomachs. 
 
Fig. 1-5.  Nissl-stained photomicrograph (A) and micro-autoradiogram (B) of the rat stomach. 
Nerve cells BA 20um20um Nerve cells
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Thirty mg/kg of [
14
C]acotiamide (20.6 MBq/kg) were administered subcutaneously to rats and the 
stomach was excised at 30 min after the administration. The stomach was embedded with OCT 
compound. Embedded stomach was cut into 6-μm-thick sections. Serial sections were attached onto 
glass slides covered with emulsion for the micro-autography and without emulsion for Nissl staining. 
For Nissl staining, sections were dehydrated in ethanol, rehydrated in distilled water and submerged in 
0.1% cresyl violet solution for approximately 30 min. Sections were dehydrated in ethanol, immersed 
in xylene, and covered with a coverslip. For the micro-autoradiography, sections were dried completely, 
then exposed in a refrigerator at 4°C for 2 weeks. Sections were developed, subjected to hematoxylin 
and eosin staining, and finally covered with a coverslip. Scale bars represent 20 μm. The red arrows 
indicate nerve cells. 
 
Finally, it should be notified that radioactivity is not always identical to acotiamide 
but can be metabolites of acotiamide or the mixture of acotiamide and its metabolites. 
Although we do not have direct evidence that radioactivity in the stomach mainly 
represents unchanged acotiamide, the concentration of acotiamide in the homogenate of 
rat stomach determined by high performance liquid chromatography reported previously 
[17] is not so different from the concentration of the radioactivity in the rat stomach found 
in the present study. Thus, the radioactivity found in the rat stomach is considered to be 
mainly unchanged acotiamde. In the case of dogs, the concentration of acotiamide in the 
homogenate of stomach has not been reported. However, plasma concentration-time 
profiles of acotiamide and radioactive acotiamide after the administration of the same dose 
of acotiamide as the present study to dogs indicate that plasma concentration of unchanged 
acotiamide at 30 min (equal to the sampling time of dog stomach in the present study) 
after the oral administration is almost identical to that of radioactivity at 30 min after the 
oral administration of the same dose of [
14
C]acotiamide to dogs (Yoshii et al., unpublished 
observation). The findings suggest that radioactivity mainly represents unchanged 
acotiamide at least in plasma at 30 min after the administration of [
14
C]acotiamide. The 
findings also suggest that acotiamide is not extensively metabolized at 30 min and 
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unchanged acotiamide appears to predominantly distribute into the stomach at 30 min after 
the oral administration to dogs. Thus, the radioactivity found in the dog stomach is also 
considered to be mainly unchanged acotiamide. 
In conclusion, the results of the present study showed that the radioactivity distributes 
into the myenteric plexus, a putative site of acotiamide action, in the muscular layer of the 
rat and dog stomachs, and that the concentrations of radioactivity around the myenteric 
plexus are estimated to be adequate to inhibit AChE in rats and dogs. Since the dose of 
acotiamide used in the present study was enough to exhibit pharmacological action in rats 
and dogs [17,26], the present findings suggest that inhibition of gastric AChE is a major 
mechanism of action responsible for the pharmacological effects of acotiamide on the 
gastrointestinal tract of rats and dogs, and may be for the therapeutic effects on the 
symptoms of patients with FD. 
3.4. Summary 
Acotiamide is the first-in-class drug for the treatment of functional dyspepsia. Although 
pharmacological and therapeutic actions of acotiamide are thought to be derived from its 
inhibitory effects on AChE, whether the concentration of acotiamide at the site of action is 
sufficient to inhibit AChE remains unclear. Since major site of acotiamide action is 
thought to be the cholinergic nerve terminals in gastric myenteric plexus, we studied the 
distribution of [
14
C]acotiamide into gastric myenteric plexus. 
Distribution of [
14
C]acotiamide was evaluated using macro- and micro-autoradiography 
in rats and dogs. 
The results of macro-autoradiography showed the concentration of radioactivity was 
27.9 μM in rat stomach, which was 12 times higher than IC50 of acotiamide for rat AChE. 
Being different from rats, the distribution of radioactivity in the muscular layer was 
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distinguishable from that in the mucosal layer in dog stomach. The concentration of 
radioactivity in the muscular layer of dog stomach (1.41 μM) was approximately 
two-times lower than those in the mucosal layer, however, it was approximately 1.2 times 
higher than IC50 of acotiamide for dog AChE. The results of micro-autoradiography also 
showed the radioactivity distributed homogenously in the muscular layer of rat stomach, 
suggesting the concentration of radioactivity around the ganglion of myenteric plexus is 
similar to that in the muscular layer of stomach. 
These findings suggest acotiamide distributes to the myenteric plexus of stomach, a 
putative site of acotiamide action, with adequate concentrations to inhibit AChE, in both 
of rat and dog stomachs. 
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4. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for 
the treatment of functional dyspepsia, in rat stomach 
4.1. Introduction 
Acotiamide is distributed around nerve cells in the myenteric plexus of stomach; 
however, the mechanism of distribution of acotiamide from blood to stomach has not been 
clarified. To investigate the tissue distribution of acotiamide in rats, the steady state 
distribution of acotiamide was evaluated in two different muscle tissues, stomach and 
skeletal muscle, using a constant-rate infusion of the drug into rats. Further, to elucidate 
the distribution mechanism of acotiamide to the stomach, in vitro binding studies were 
performed with plasma and stomach tissue homogenate. The initial uptake clearance was 
also determined by integration plot analysis for several tissues, including stomach and 
skeletal muscle. Furthermore, to determine whether the distribution of acotiamide was 
concentrative, the stomach-to-plasma unbound concentration ratio (Cst,u,cyt/Cp,u) was 
determined. 
4.2. Materials and methods 
4.2.1. Chemicals 
N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thiaz
ole-4-carboxamide monohydrochloride trihydrate (acotiamide hydrochloride, 
Z-338/YM443) and 
(N-[2-(diisopropylamino)ethyl]-2-[(2,4,5-trimethoxybenzoyl)amino]-1,3-thiazole-4-carbo
xamide (ID951551, an internal standard for liquid chromatography) were synthesized in 
the central research laboratories of Zeria Pharmaceutical Co., Ltd. (Saitama, Japan). 
[
14
C]Acotiamide (2.26 GBq/mmol) was synthesized by GE Healthcare UK Ltd. 
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(Buckinghamshire, England). [
3
H]Inulin (5.37 MBq/mg) was purchased from American 
Radiolabeled Chemicals, Inc. (St. Louis, MO). All other chemicals were reagent grade. 
4.2.2. Animals 
Male Sprague-Dawley rats (six to seven weeks of age) were obtained from Charles 
River Japan, Inc. (Kanagawa, Japan). Animals were housed under standard controlled 
environmental conditions at 23 ± 3°C and 55% ± 20% humidity, with 12-hour light/dark 
cycles (7:00-19:00, light) and food (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan) and 
water available ad libitum. The rats were allowed to acclimate to laboratory conditions for 
at least one week prior to performing the experiments. All animal experiments were 
approved by the Animal Care and Use Committee of the Central Research Laboratories of 
Zeria Pharmaceutical Co., Ltd. 
4.2.3. In vivo infusion study 
For the infusion of acotiamide, rats were first anesthetized with pentobarbital (50 mg/kg), 
and the femoral artery and vein were cannulated with heparinized polyethylene tubing. 
Acotiamide was dissolved in a 5% injectable glucose solution and then infused through 
the femoral vein cannula at a flow rate of 20 µl/min. The infusion rates were set at 2, 5, 10, 
20, 50, and 100 nmol/min/kg. Serial blood samples were collected from the arterial 
cannula before and 60, 90, 100, 110, and 120 min after drug administration, and were then 
centrifuged to separate the plasma. The abdomen was opened 120 min after starting the 
infusion, and the stomach and skeletal muscle tissues were immediately excised, rinsed 
with distilled water, weighed, and homogenized in distilled water to form a 20% (w/v) 
homogenate. The concentrations of acotiamide in plasma, stomach tissue, and skeletal 
muscle tissue were determined by liquid chromatography mass spectrometry (LC-MS/MS), 
as described below. 
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4.2.4. Kinetic analysis of the in vivo stomach distribution of acotiamide 
Total body clearance (CLtot), which was based on in vivo infusion data, was calculated 
according to the following equation. 
ss,aratetot CICL   ····································································· Eq. 1-1 
where Irate is the infusion rate of acotiamide, and Ca,ss is the arterial plasma concentration 
of acotiamide 120 min after starting the infusion. 
Kinetic parameters for the distribution of acotiamide were determined from the plasma 
and stomach tissue concentration data obtained from the acotiamide infusion using 
WinNonlin (Pharsight Corp., Mountain View, CA). The Kp,app,in vivo of acotiamide was 
defined by the following equation: 
p,up,f
t,ft,b
ss,atvivo in,app,p
fC
CC
CCK
+
==  ·················································· Eq. 1-2 
where Ct is the concentration of acotiamide in stomach tissue, Cb,t and Cf,t are the bound 
and unbound stomach tissue concentration of acotiamide, respectively, and fu,p is the 
unbound fraction of acotiamide in plasma (0.128), which was calculated from the plasma 
protein binding parameters under linear conditions, as described below, since the 
examined unbound plasma concentration was markedly lower than the dissociation 
constant in vitro (Kd, in vitro). 
Assuming that both saturable and non-saturable binding are involved in tissue 
distribution, Cb,t was defined by the following equation: 
  t,finvivo
t,finvivo,d
t,finvivomax,
t,b
CN
CK
CB
C 


  ·················································· Eq. 1-3 
Then, Eq. 1-2 can be expressed by: 
p,up,f
t,ft,finvivo
t,finvivo,d
t,finvivomax,
vivo in,app,p
fC
CCN
CK
CB
K












 ··································· Eq. 1-4 
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Assuming that the unbound concentration in stomach tissue (Cf,t) is equal to that of 
plasma (Cf,p) in Eq. 1-4: 
pu,vivo in
ssa,
pu,
vivo ind,
vivo inmax,
vivo inapp,p, f)N(
)C
f
K
(
B
K 

 1  ····································· Eq. 1-5 
where Bmax,in vivo is the binding capacity, Kd,in vivo is the dissociation constant, and Nin vivo 
is the proportionality constant for nonspecific binding, Ca,ss represents the steady-state 
plasma concentration of acotiamide. The first and second terms on the right side of Eq. 1-5 
describe the displaceable (saturable) Kp value (Kp,disp) and non-displaceable 
(non-saturable) Kp value (Kp,nondisp), respectively. The Kd,in vivo, Bmax,in vivo, and Nin vivo 
values were obtained by fitting the data sets of Kp,app,in vivo and Ca,ss to Eq. 1-5. 
4.2.5. In vitro binding study 
Rats were anesthetized, and plasma and stomach tissue were collected. The excised 
stomach tissue was rinsed with 250 mM sucrose containing 50 mM Tris-HCl buffer (pH 
7.4), weighed, and homogenized in the identical buffer to form a 20% (w/v) homogenate. 
The in vitro binding rates of acotiamide were determined by an ultracentrifugation 
method. Briefly, acotiamide was added to the 20% (w/v) homogenate of stomach tissue 
and the collected plasma to final concentrations of 0.05 to 10,000 μM and 0.01 to 2,000 
μM, respectively, and the resulting mixtures were then ultracentrifuged at 220,000 × g for 
18 h at 4°C. The concentration of acotiamide in the supernatant following 
ultracentrifugation was determined by LC-MS/MS, as described below. 
The unbound fraction (fu,p and fu,homo for plasma and stomach tissue homogenate, 
respectively) was calculated as follows: 
samplesuphomou,pu,
CCfor f 
 ·························································· Eq. 1-6 
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where Csample is the nominal concentration in the stomach tissue or plasma sample, and 
Csup is the concentration in the supernatant after ultracentrifugation. 
The value of the unbound fraction in 100% of the stomach tissue homogenate (fu,homo) 
was extrapolated from the observed fu values (fu,homo(20%)) as follows [28]: 
d)f(
d1
f
homo(20%)u,
homou,
111 

 ···················································· Eq. 1-7 
where d is the dilution factor (equal to 5) for the stomach tissue homogenate. 
4.2.6. Determination of binding parameters 
Parameters for binding to plasma and stomach tissue were calculated using Eq. 1-8 and 
Eq. 1-9, respectively. 
fin vitro
fin vitro,d
fin vitromax,
b CN
CK
CB
C 



 ····························································· Eq. 1-8 
fvitro inb
CNC 
 ·············································································· Eq. 1-9 
where Cb and Cf are the bound and unbound, respectively, stomach tissue or plasma 
concentrations of acotiamide, Bmax,in vitro is the binding capacity, Kd,in vitro is the dissociation 
constant, and Nin vitro is the proportionality constant for nonspecific binding. The above 
equation was fit to the binding data sets to obtain estimates of binding parameters by the 
nonlinear least squares method using WinNonlin.  
The unbound fraction of acotiamide in plasma (fu,p) and stomach tissue (fu,t) in the linear 
region was estimated from the binding parameters by Eq. 1-10 and Eq. 1-11, respectively. 
vitro in
vitro in,d
vitro inmax,
p,u
N
K
B
f


1
1
 ························································ Eq. 1-10 
vitro in
t,u
N
f


1
1
 ····································································· Eq. 1-11 
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The in vitro tissue-to-plasma concentration ratio (Kp,app,in vitro) was predicted from the in 
vitro tissue binding data alone, without assuming the existence of any concentrative influx 
and/or efflux processes, and was expressed as follows: 
t,uu,pvitro in,app,p ffK   ································································· Eq. 1-12 
4.2.7. Integration plot analysis  
Rats were anesthetized with pentobarbital (50 mg/kg), and the femoral artery was 
cannulated with heparinized polyethylene tubing. After intravenous bolus administration 
of [
14
C]acotiamide (0.185, 0.924, 1.85, and 9.24 μmol/kg) including [3H]inulin (0.1 
mg/kg), blood samples were collected from the arterial cannula at 10, 20, 30, and 45 s, and 
at 1, 1.5, 2, 3, and 5 min. In addition, at the 30 s, and 1, 2, 3, and 5 min time points, the 
abdomen was opened, and the stomach, skeletal muscle, liver, kidney, and brain tissues 
were excised and the tissue weights were then measured. After solubilization of the tissue 
samples with a Soluen-350 tissue solubilizer (PerkinElmer, Waltham, MA), the 
radioactivities in blood and tissues were measured using a TRI-CARB 2900TR liquid 
scintillation analyzer (PerkinElmer). 
When tissue uptake of acotiamide was measured within a short time period, during 
which the efflux and/or elimination of radioactivity from tissues were negligible, tissue 
distribution was described by linear kinetics, as described by Eq. 1-13. 
t,bappinf,t
CCLdtdX   ······························································ Eq. 1-13 
where Xt is the amount of [
14
C]acotiamide in the tissue at time t, CLinf,app is the initial 
uptake clearance, and Cb,t is the blood concentration of acotiamide at time t. Integration of 
Eq. 1-13 gives 
t,bdtappinf,t
CVAUCCLX 
0
 ··················································· Eq. 1-14 
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where AUC0-t represents the area under the Cb time curve from time 0 to t, Vd represents 
the distribution volume of tissue compartments that equilibrates rapidly with the blood 
compartment. Eq. 1-14 divided by Cb,t gives 
dt,btappinf,t,btp
VCAUCCLCXK 
0
 ······································· Eq. 1- 15 
where Kp (Xt/Cb,t) is the tissue-to-blood concentration ratio at time t, with units of 
milliliters per gram of tissue. 
The CLinf,app was obtained from the slope of the plot of Xt/Cb,t (on the ordinate) vs. 
AUC0–t/Cb,t (on the abscissa)
 
[29, 30]. The initial uptake clearance (CLinf,r) for the kidney 
was determined from CLinf,app, fu,b, and glomerular filtration rate (GFR) by use of the 
following equation: 
GFRfCLCL b,uappinf,rinf,   ······················································ Eq. 1-16 
where the GFR was taken as the CLinf,app of inulin, fu,b is the unbound fraction of 
acotiamide in the blood, which was calculated by dividing fu,p by the blood-to-plasma 
concentration ratio (0.84), and CLinf,app represents a hybrid parameter of the 
permeability-surface area product (PSinf,app) and blood flow (Q, ml/min/g of tissue). The 
blood-flow independent parameter, fu,b·PSinf,app was calculated using Eq. 1-17 assuming 
the well-stirred model
 
[31, 32]. 
appinf,
appinf,
appinf,b,u
Q-CL
QCL
PSf

  ························································· Eq. 1-17 
where Q was calculated from tissue weight and tissue blood flow. The tissue weight and 
blood flow parameters for each tissue were taken from Hosseini-Yeganeh and McLachlan 
[33]. Tissue weight was converted from the tissue volume based on the assumption that 
tissue specific gravity equals 1 g/ml. 
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4.2.8. Determination of the stomach-to-plasma unbound concentration ratio of 
acotiamide 
Plasma and stomach tissue homogenate were prepared from rats infused with 2 
nmol/min/kg acotiamide in the identical manner as described for the in vivo infusion 
experiment, with the exception of the homogenate solvent used. Stomach tissue was 
homogenized in 250 mM sucrose containing 50 mM Tris-HCl buffer (pH 7.4) to form a 
20% (w/v) homogenate. A portion of stomach tissue homogenate was centrifuged at 
105,000 × g for 60 min at 4°C to obtain the cytosol fraction. The remaining stomach tissue 
homogenate, cytosol fraction, and plasma were ultracentrifuged at 220,000 × g for 18 h at 
4°C, and the resultant supernatants were collected. The concentrations of acotiamide in the 
plasma, stomach tissue homogenate, cytosol, and collected supernatants were determined 
by LC-MS/MS, as described below. 
The unbound fraction (fu) of acotiamide was calculated as described for the in vitro 
binding study. The fraction of acotiamide distributed to the cytosol was calculated as 
follows: 
  
  111
111
20
20



%)(ohom,u
%)(cyt,u
cyt
fd
fd
Fract   ··············································· Eq. 1-18 
where d is the dilution factor (equal to 5) for the stomach tissue homogenate, and 
fu,cyt(20%) and fu,homo(20%) are the unbound fractions in the cytosol and stomach tissue 
homogenate, respectively. The unbound concentration of acotiamide in the cytosol 
fraction (Cst,u,cyt) was calculated as follows: 
cyt,ucytstcyt,u,st
fFractCC    ······················································· Eq. 1-19 
where Cst represents the concentration of acotiamide in the stomach tissue, and fu,cyt is 
the unbound fraction in 100% of the cytosol fraction extrapolated from the observed fu 
values (fu,cyt(20%)). The Cst,u,cyt was adjusted based on the assumption that the specific 
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gravity of the cytosolic fluid volume is equal to 1 g/ml of tissue. The unbound 
concentration ratio of stomach cytosol to plasma (Cst,u,cyt/Cp,u) was then calculated. 
4.2.9. Quantification of acotiamide by LC-MS/MS 
For the quantification of acotiamide, 50 μl of each plasma sample was mixed with 10 μl 
50% methanol, and 500 μl methanol and an internal standard were then added to the 
resulting solutions. After centrifuging the mixtures, the supernatants were collected and 
subjected to LC-MS/MS.  
For the stomach and skeletal muscle tissues, 100 μl of each homogenate was mixed with 
20 μl 50% methanol, and 480 μl methanol was then added to the resulting solutions. 
Following centrifugation, an internal standard was added to 400 μl of supernatant, and 300 
μl of this mixture was filtrated using a centrifugal filter. Following filtration, 75 μl 
distilled water was added to the filtrate, and 10 μl aliquots were then subjected to 
LC-MS/MS.  
Acotiamide in the cytosol fraction and the supernatants of plasma, stomach tissue 
homogenate, and cytosol fraction was quantitated by first mixing 200 μl of each sample 
with 20 μl dimethylsulfoxide, and 200 μl 5% phosphoric acid and an internal standard 
were then added to the resulting solutions. The mixtures were applied to an Oasis HLB 
μElution solid-phase extraction plate (Waters, Milford, MA), and the analytes were eluted 
with 100 μl methanol. Distilled water (100 μl) was added to each eluate, and 10 μl aliquots 
were then subjected to LC-MS/MS. 
LC-MS/MS analysis was performed on an API 4000 tandem mass spectrometer 
(Applied Biosystems, Inc., Foster City, CA) equipped with a 1100 series HPLC system 
(Agilent Technologies, Palo Alto, CA) using a reverse phase column (CAPCELL PAK C18 
MGII; Shiseido, Tokyo, Japan). Electrospray ionization was performed in the positive-ion 
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mode. Acotiamide and an internal standard were quantified using the selected 
reaction-monitoring mode with a flow rate of 0.8 ml/min methanol/20 mM ammonium 
acetate (pH 6.0) (6: 4). The monitoring ions for acotiamide and the internal standard were 
m/z 451 → m/z 271 and m/z 465 → m/z 364, respectively. 
4.3. Results 
4.3.1. Distribution of acotiamide to the stomach and skeletal muscle in rats  
The distribution of acotiamide to the stomach and skeletal muscle of rats was determined 
after constant-rate infusion of several doses of acotiamide for 120 min (Fig. 2-1). At each 
infusion dose, the plasma concentrations of acotiamide maintained a steady level for 30 
min until the termination of infusion (data not shown). The tissue-to-plasma concentration 
ratio (Kp,app,in vivo) of acotiamide for the stomach was 4.1 ± 0.3 and 2.4 ± 0.3 ml/g of tissue 
at 2 nmol/min/kg and 100 nmol/min/kg, respectively, indicating that the stomach 
distribution was dependent on the plasma concentration (Fig. 2-1). In contrast, the Kp,app,in 
vivo for skeletal muscle was independent of the plasma acotiamide concentration, with 
values of approximately 0.8 ml/g of tissue determined for all infusion doses (Fig. 2-1). 
The total body clearances (CLtot) of acotiamide ranged from 34.1 ± 6.1 to 38.7 ± 3.9 
ml/min/kg at all examined doses, and increasing the infusion rate did not affect the CLtot. 
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Fig. 2-1.  Tissue-to-plasma concentration ratio (Kp) versus plasma concentration in rat stomach and 
skeletal muscle 120 min after starting constant-rate infusion of acotiamide. 
Acotiamide was infused at rates of 2, 5, 10, 20, 50, and 100 nmol/min/kg. The solid line represents the 
calculated curve obtained by fitting to Eq. 1-5 (see the Materials and methods). Kd,in vivo = 0.292 (0.062) 
μM, Bmax,in vivo = 7.00 (2.08) nmol/g of tissue, and Nin vivo = 7.30 (2.32); the values in parentheses 
represent the S.E. for the nonlinear least squares analysis. The data points and error bars represent the 
mean ± S.D. of six independent experiments. 
4.3.2. Binding parameters for acotiamide calculated from in vivo infusion study. 
The in vivo binding parameters of acotiamide were calculated according to Eq. 1-5 using 
the data obtained from the in vivo constant-rate infusion experiments (Fig. 2-1). The 
dissociation constant for the saturable component (Kd,in vivo) was determined to be 0.292 
μM. 
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4.3.3. Plasma and stomach tissue protein binding of acotiamide 
To evaluate the involvement of tissue protein binding in acotiamide distribution, the 
binding of acotiamide to plasma and stomach tissue protein was next examined (Fig. 2-2). 
The binding of acotiamide to plasma protein was concentration dependent (Fig. 2-2A), 
indicating two components involved. In contrast, the binding of acotiamide by stomach 
tissue protein showed a linear relationship with the concentration of acotiamide (Fig. 
2-2B). The binding parameters for the two processes are summarized in Table 2-1. In 
addition, we also predicted the Kp,app,in vitro from the unbound fraction of acotiamide in the 
plasma and stomach tissue, which was determined to be 2.2 (Table 2-1). 
 A B 
  
Fig. 2-2.  Protein binding of acotiamide by plasma (A) and stomach tissue (B). 
Each data point represents the mean value of triplicate samples. Cb represents the concentration of 
acotiamide bound to plasma or stomach tissue protein, and Cf is the unbound concentration of 
acotiamide. Cb and Cf of the stomach were expressed as 100% of the stomach tissue. The solid line in A 
and B represents the fitted line (corresponding to Eq. 1-8 and 1-9, respectively). 
 
Table 2-1.  The binding parameters of acotiamide, free fractions in plasma and stomach tissue, and 
stomach tissue-to-plasma concentration ratio 
Matrices Bmax,in vitro
a Kd,in vitro 
(μM) 
Nin vitro fu Kp,app,in vitro 
Plasma 479 (102) 87.0 (25.2) 1.33 (0.14) 0.128 2.2 
Stomach – – 16.4 (1.0) 0.0575  
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a
 The unit is μM and nmol/g of tissue for plasma and stomach, respectively. The values in parentheses 
represent the S.E. for the nonlinear least squares analysis. 
4.3.4. Integration plot analysis 
The time profiles of acotiamide concentrations in the blood and various tissues were 
subjected to kinetic analyses after intravenous bolus administration of acotiamide at 
multiple doses. The unbound blood concentration ranged from 0.116 to 7.42 μM at the 
initial sampling point of the tissues (30 s) for doses ranging from 0.185 to 9.24 μmol/kg, 
suggesting that the uptake experiments were conducted in the concentration range 
including Kd,in vivo. In Fig. 2-3, the Xt/Cb,t and AUC0-t/Cb,t are plotted (integration plot) at 
an acotiamide dose of 0.185 μmol/kg, with the slope of each curve corresponding to the 
initial tissue uptake clearance (CLinf,app). Notably, the slope for acotiamide was markedly 
larger than that for inulin, an extracellular marker, in the stomach and liver (Fig. 2-3A and 
Fig. 2-3D, respectively), and was slightly larger than that for inulin in the skeletal muscle 
and kidney (Fig. 2-3B and Fig. 2-3E, respectively). In brain tissue, however, the slope for 
acotiamide was almost equal to that for inulin (Fig. 2-3C). The CLinf,app for acotiamide in 
the stomach, liver, and kidney was higher than that in the skeletal muscle and brain. In all 
of the examined tissues, fu,b∙PSinf,app, which is independent of blood flow, was calculated 
using the CLinf,app in the well-stirred model and was found to decrease with increasing 
acotiamide dosage for all examined tissues, with the exception of the brain (Fig. 2-4). The 
fu,b∙PSinf,app was lower than the blood flow rate in the stomach, skeletal muscle, and brain 
at the lowest dose of acotiamide (Fig. 2-4). 
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Fig. 2-3.  Integration plots representing acotiamide uptake by each examined tissue. 
Time profiles of acotiamide concentration in the blood and stomach (A), skeletal muscle (B), brain (C), 
liver (D), and kidney (E) were determined after bolus injection (0.185 μmol/kg) into rats. The slope 
represents the initial uptake clearance of acotiamide, which was determined to be 0.269, 0.0242, 
0.00922, 0.558, and 1.49 ml/min/g of tissue for the stomach, skeletal muscle, brain, liver, and kidney, 
respectively. The broken line in the integration plots represents the uptake of [
3
H]inulin. The data 
points and error bars represent the mean ± S.D. of three independent experiments. 
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Fig. 2-4.  fu,b·PSinf,app for acotiamide in various tissues after intravenous bolus administration. 
Tissue blood flow was 1.0, 0.061, 1.1, 1.1, and 2.5 ml/min/g of tissue for the stomach, skeletal muscle, 
brain, liver, and kidney, respectively, in rat (body weight 250 g) [33]. 
4.3.5. Unbound concentration ratio of stomach to plasma 
To determine whether the distribution of acotiamide was concentrative, the 
stomach-to-plasma unbound concentration ratio (Cst,u,cyt/Cp,u) was determined. The free 
fractions of acotiamide in the examined biological matrices are summarized in Table 2. 
The fraction of acotiamide distributed to the stomach cytosol (Fractcyt) is also listed in 
Table 2. From these calculations, the Cst,u,cyt/Cp,u was determined to be 2.8 ± 0.8 (Table 2). 
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Table 2-2.  The unbound concentration ratio of stomach to plasma (Cst,u,cyt/Cp,u) after the 
constant-rate infusion of acotiamide at a dose of 2 nmol/min/kg to rats 
Matrices fu Fractcyt
a
 Concentration (μM) Cst,u,cyt/Cp,u 
Plasma 0.149 ± 0.041 – 0.00739 ± 0.00319b – 
Stomach 0.868 ± 0.126
c
 0.120 ± 0.033 0.0193 ± 0.0063
d
 2.8 ± 0.8 
a
 Fraction of acotiamide distributed to the stomach cytosol. 
b
 Unbound concentration of acotiamide in plasma (Cp,u, μM). 
c
 Unbound fraction extrapolated from fu,cyt(20%) (fu,cyt). 
d
 Unbound concentration of acotiamide in the stomach cytosol (Cst,u,cyt). 
Each value represents the mean ± S.D. of six rats. 
4.4. Discussion 
Acotiamide hydrochloride (Z-338/YM443) is a member of new class of gastroprokinetic 
agents currently being developed for the treatment of FD. It is thought that acotiamide 
ameliorates symptoms of FD by improving delayed gastric emptying through inhibition of 
AChE in the stomach. However, as AChE distributes to various tissues, including muscle 
and brain, the objective of the present study was to assess the distribution of acotiamide to 
tissues, and to elucidate the mechanism for the distribution of acotiamide to the stomach. 
The distribution of drugs in the body is determined by numerous factors, including tissue 
blood flow, basolateral membrane permeability, and cell-binding components. The 
mechanisms for the selective tissue distribution of drugs are likely to involve tissue 
binding, higher tissue uptake, and/or lower efflux from tissues. Here, to determine the total 
sum of these mechanisms, the distribution of acotiamide was initially evaluated at steady 
state. The tissue-to-plasma concentration ratio (Kp,app,in vivo) of stomach tissue was higher 
than unity at all examined doses (Fig. 2-1). The Kp,app,in vivo of stomach tissue decreased 
with increasing plasma concentrations of acotiamide (Ca,ss), indicating that a saturable 
component was involved in the stomach distribution (Fig. 2-1). Therefore, we speculate 
that the distribution of acotiamide into the stomach involves a specific mechanism.  
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The contribution of tissue protein binding on the distribution of drugs has previously 
been reported by Wierzba et al.
 
[34], who demonstrated that the tissue distribution of 
vincristine could be predicted by tubulin concentrations in the respective tissues [34]. Here, 
the binding parameters of acotiamide were estimated from in vivo infusion experiments. 
The in vivo dissociation constant (Kd,in vivo) was estimated to be 0.292 μM (Fig. 2-1), 
indicating that a component specifically interacts with acotiamide in the stomach. 
However, in vitro binding revealed that stomach protein binding did not saturate at 
acotiamide concentrations between 0.05 to 10,000 μM (Fig. 2-2B), although the Kp,app,in vivo 
decreased by approximately 60% of the highest value for the unbound plasma 
concentration of acotiamide (0.380 μM) at the highest infusion rate (Fig. 2-1). The Kp,app,in 
vitro, which was predicted to be 2.2 from free fractions of the plasma and stomach tissue 
based on Eq. 1-12, was not consistent with the Kp,app,in vivo at a dose of 2 nmol/min/kg 
(Table 2-1, Fig. 2-1). However, at a dose of 100 nmol/min/kg, the Kp,app,in vivo was 
determined to be 2.4 ml/g of tissue, which was consistent with Kp,app,in vitro, suggesting that 
the nonspecific binding of acotiamide to stomach tissue proteins may be involved in the 
distribution of acotiamide into stomach tissue at the highest examined infusion rate (Table 
2-1, Fig. 2-1). Since Kp,app,in vivo was larger than Kp,app,in vitro at the lowest infusion rate of 
acotiamide, a mechanism other than tissue protein binding appears to be involved in the 
specific distribution of acotiamide into the stomach. 
Transporters are actively involved in the specific distribution of drugs to target organs. 
The transporter responsible for the uptake of xenobiotics across basolateral membranes 
has been identified in clearance organs, including the liver and kidney [35,36,37]. 
However, no transport proteins that are able to facilitate the uptake of a wide variety of 
xenobiotics from intra-vascular spaces to the stomach have been identified. To evaluate 
the involvement of transport in the distribution of acotiamide, the initial uptake clearance 
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(CLinf,app) was determined. The saturable uptake of acotiamide by stomach tissue was 
observed at the blood unbound concentration range from 0.116 to 7.42 µM (Fig. 2-3A), 
while the Kp,app,in vivo also showed saturation at the unbound concentration range of 
0.00699 to 0.380 μM (Fig. 2-1). As these concentration ranges are similar, uptake 
processes appear to play a role in the specific distribution of acotiamide to the stomach. In 
addition, the fu,b∙PSinf,app was lower than the blood flow rate in stomach tissue, suggesting 
that the permeability of acotiamide might be the rate-limiting step in the uptake by 
stomach tissue (Fig. 2-4). Moreover, the unbound concentration ratio of stomach to 
plasma (Cst,u,cyt/Cp,u), which is minimally affected by the tissue binding to cytosolic 
proteins or organelles, was higher than unity (Table 2-2). These findings suggest that an 
active transport system is involved in the distribution of acotiamide to the stomach.  
We determined that the Kp,app,in vivo of skeletal muscle (approximately 0.8 ml/g of tissue) 
was independent of the Ca,ss (Fig. 2-1), while the fu,b∙PSinf,app exhibited only minimal dose 
dependence (Fig. 2-4). This discrepancy likely resulted from the experimental conditions, 
as the uptake study was performed within a short time period to facilitate monitoring of 
only the uptake process, during which time the efflux and/or elimination from the tissues 
were negligible, whereas the conditions of the constant-rate infusion experiments may 
have been closer to physiological conditions. Thus, the transport of acotiamide may only 
minimally contribute to the distribution to skeletal muscle. Taken together, these results 
indicate that carrier-mediated concentrative uptake processes (i.e., transport systems) play 
an important role in the distribution of acotiamide to the stomach, but not the skeletal 
muscle, in rats. 
In contrast to a number of other motility modifying drugs, acotiamide does not increase 
prolactin levels or extrapyramidal symptoms during or after the period of exposure [38]. 
Here, we clearly demonstrated that acotiamide does not distribute to the brain, because the 
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Xt/Cb for acotiamide was less than or equal to the Xt/Cb for inulin in the examined brain 
tissues (Fig. 2-3). Since the fu,b∙PSinf,app of the brain was approximately 100-fold lower 
than the blood flow rate (Fig. 2-4), it appears the blood-brain barrier prevents acotiamide 
from penetrating the brain. The poor distribution of acotiamide to the brain is a desirable 
pharmacological property of this novel AChE inhibitor. 
Following oral administration, acotiamide is mainly metabolized to glucuronide 
conjugates through reactions catalyzed by members of the human uridine 
5'-diphosphate-glucuronosyltransferase (UGT) 1A family, particularly UGT1A9 and 1A8 
[39]. Messenger RNAs of UGTs have also been detected in the kidney and liver in rats 
[40,41]. In the present study, the fu,b·PSinf,app of the rat kidney and liver was equal to or 
higher than the blood flow rate of each tissue at a dose of 0.185 μmol/kg (Fig. 2-4). In 
addition, the sum of the CLinf,app of the kidney and liver at a dose of 0.185 μmol/kg, which 
was extrapolated to whole tissues based on the weight of each tissue of whole animals 
(22.1 and 23.0 ml/min/kg, respectively), was close to the total body clearance based on the 
blood concentration (40.6 to 46.1 ml/min/kg), which was converted from the CLtot values 
obtained from the constant-rate infusion study. Taken together, these findings suggest that 
the overall elimination of acotiamide is governed by tissue uptake processes in the liver 
and/or kidney of rats. 
In conclusion, we have demonstrated that acotiamide is selectively distributed to the 
stomach in rats, and that the specific distribution may be mediated by a carrier-mediated 
uptake process. Thus, acotiamide appears to be a promising and highly selective drug for 
the treatment of FD. 
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4.5. Summary 
Acotiamide improves gastric motility by inhibiting AChE activity in stomach; however, 
the mechanism of distribution of acotiamide from blood to stomach has not been clarified. 
Here, the tissue distribution of acotiamide was investigated in rats. The tissue-to-plasma 
concentration ratio (Kp,app,in vivo) for stomach decreased from 4.1 to 2.4 ml/g of tissue at 
steady state with increasing plasma concentrations, whereas the Kp,app,in vivo for skeletal 
muscle was much lower and constant regardless of the concentration of acotiamide in 
plasma. In vitro binding to stomach tissue protein exhibited a linear profile, with a 
predicted Kp,app,in vitro of 2.2 from free fractions under linear conditions. Therefore, protein 
binding to stomach tissue might only play a limited role in the stomach distribution of 
acotiamide. The influx permeability (fu,b·PSinf,app) in the stomach exhibited dose-dependent 
saturation at the lowest range of examined blood unbound concentrations of acotiamide, 
whereas that in skeletal muscle exhibited only minimal dose dependence. In addition, the 
unbound concentration ratio of stomach to plasma (2.8) at steady state was markedly 
higher than unity. Taken together, these results suggest that carrier-mediated concentrative 
uptake processes play an important role in the distribution of acotiamide to the stomach, 
but not skeletal muscle. 
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5. Physiologically-based pharmacokinetic and pharmacodynamic modeling for 
the inhibition of acetylcholinesterase by acotiamide, a novel gastroprokinetic 
agent for the treatment of functional dyspepsia, in rat stomach 
5.1. Introduction 
In previous chapter, acotiamide was highly distributed into the stomach after the 
intravenous administration of acotiamide to rats [20]. Moreover, the integration plot 
analysis indicated that acotiamide was uptaken by at least two stomach compartments, 
which rapidly and slowly equilibrated with the blood [20]. However, as the role of these 
stomach compartments were unsettled, the relationship of the blood and stomach 
concentration of acotiamide with the pharmacological action remains unclear. 
The purpose of this study was to elucidate the relationship of the blood and stomach 
concentration of acotiamide with the pharmacological action. For the purpose, we 
developed a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) 
model to describe the profiles for concentration of acotiamide and ACh in rats. In this 
model, the stomach compartments rapidly and slowly equilibrated with the blood were 
assumed as vascular space and extravascular compartment in rat stomach, respectively. In 
addition, ACh was chosen as the marker for the pharmacological action of acotiamide 
because the reported index like the motility index might be improper for the describing the 
time course change for the pharmacological action of acotiamide. The profiles for blood 
and stomach concentration of acotiamide were determined to characterize the 
pharmacokinetic parameters. Moreover, to confirm the elevation of ACh derived from the 
inhibition of AChE by acotiamide, the inhibitory effect of acotiamide on AChE in vitro 
and the increase of ACh in the stomach were determined. 
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5.2. Materials and Methods 
5.2.1. Chemicals 
N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thi
azole-4-carboxamide monohydrochloride trihydrate (acotiamide hydrochloride, 
Z-338/YM443 and 
N-[2-(diisopropylamino)ethyl]-2-[(2,4,5-trimethoxybenzoyl)amino]-1,3-thiazole-4-carbox
amide (ID951551, an internal standard for the determination of acotiamide) were 
synthesized in the central research laboratories of Zeria Pharmaceutical Co., Ltd. (Saitama, 
Japan). 1,1-Dimethyl-4-acetylthiomethylpiperidinium iodide (MATP+) was purchased 
from Dojindo Laboratories (Kumamoto, Japan). 5,5'-Dithiobis-2-nitrobenzoic acid 
(DTNB), and (±)-sulpiride (an internal standard for the determination of MATP+-TNB) 
were purchased from Sigma-Aldrich Co. LLC (St Louis, MO, USA). Acetylcholine iodide 
and N-ethylmaleimide (NEM) were purchased from Wako Pure Chemical Industries 
(Osaka, Japan). Acetylcholine-d9 chloride (an internal standard for the determination of 
ACh) was purchased from Toronto Research Chemicals Inc. (Ontario, Canada). All other 
chemicals were reagent grade. 
5.2.2. Animals  
Male Sprague-Dawley rats (aged 6 to 7 weeks) obtained from Charles River Japan, Inc. 
(Kanagawa, Japan) were housed under standard controlled environmental conditions at 23 
± 3°C and 55% ± 20% humidity, with a 12-h light/dark cycle (7:00-19:00, light) and food 
(CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan) and water available ad libitum. Rats were 
allowed to acclimate to laboratory conditions for at least one week prior to performing the 
experiments. All animal experiments were approved by the Animal Care and Use 
Committee of the Central Research Laboratories of Zeria Pharmaceutical Co., Ltd. 
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5.2.3. Preparation of stomach homogenate for in vitro study  
Rats were anesthetized with isoflurane and their stomachs immediately excised after 
blood removal, rinsed with distilled water, weighed, and homogenized in distilled water to 
form a 50% (w/v) homogenate. Protein concentrations were determined using the Bio-Rad 
protein assay kit (Bio-Rad, Hercules, CA, USA). 
5.2.4. AChE activity by stomach homogenate  
AChE activity was measured using MATP+ as a substrate (50 µM), as previously 
described [42]. Normally, MATP+ is hydrolyzed by AChE and reacted with DTNB. The 
release of TNB is generally measured with a spectrophotometer at 412 nm to determine 
AChE activity. However, in the present study, background absorbance was extremely high 
in stomach homogenate (50% [w/v]), which compromised the results. We therefore 
measured the concentration of the MATP+ and TNB complex (MATP+-TNB), which was 
the result of MATP+ hydrolysis by AChE, using ultra-performance liquid chromatography 
(UPLC; Waters, Milford, MA, USA). 
The reaction medium (0.1 M Na2HPO4 and 0.1 M NaH2PO4 including 0.5% 
Triton
®
X-100, pH8.0) contained 10 mM DTNB and 2 mM NEM. Hydrolysis of MATP+ 
by AChE was initiated by adding 50 μM MATP+ to an incubation medium that included 
the stomach homogenate after preincubation at 30°C for 3 min. At designated times, 1 ml 
of methanol containing 0.1% formic acid was added to terminate the reaction, and an 
internal standard ([±]-sulpiride) was then added. Following centrifugation, the supernatant 
was evaporated until dry under nitrogen gas in a water bath at 60°C and the residue was 
dissolved in 200 µl of mobile phase B (see below for composition). The concentration of 
MATP+-TNB in each sample was determined by UPLC using a hydrophilic interaction 
chromatography (HILIC) column (ACQUITY
®
 UPLC BEH HILIC; Waters) with MATP+ 
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as the standard. Ultraviolet absorbance was monitored at 230 nm. Mobile phase A 
consisted of methanol and 5 mM ammonium acetate (pH5.0) (50:50). Mobile phase B 
consisted of acetonitrile, isopropanol and 5 mM ammonium acetate (pH5.0) (90:5:5). A 
steady gradient started at 1% mobile phase A for 5 min at a flow rate of 1.0 ml/min, 
moving then to 50% mobile phase B over the next 4 min, and finally to 1% mobile phase 
A from 9 to 12 min. 
The initial hydrolysis velocity was calculated using linear regression of the data taken 
at 60 s. The effect of acotiamide on the MATP+ hydrolysis was studied at acotiamide 
concentrations ranging from 0.05 to 25 μM. 
5.2.5. In vivo study  
For the intravenous administration of acotiamide, rats were first anesthetized with 
isoflurane. Acotiamide was dissolved in a 5% glucose solution and then injected to 
sixty-six rats in six different experiments via the femoral vein at 1.85 μmol/kg. Blood 
samples were collected from the abdominal aorta at 5, 10, 15, and 30 min and 1, 2, 4, 6, 8, 
24 and 48 h after drug administration and then centrifuged to separate the plasma. In 
addition, at each time point, the stomach was immediately excised, rinsed with distilled 
water, weighed, and homogenized in distilled water to form a 50% (w/v) homogenate. A 
portion of the homogenate from 5 min to 4 h was set aside for the determination of ACh, 
and the remainder was used for the determination of acotiamide concentration. The 
concentrations of acotiamide in plasma and stomach tissue and of ACh in stomach tissue 
were determined via liquid chromatography-mass spectrometry (LC-MS/MS) as described 
below. 
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5.2.6. Quantification of acotiamide by LC-MS/MS  
For the quantification of acotiamide, 250 μl of each plasma sample was mixed with 
10 μl of 50% methanol, 250 μl of 2% trichloroacetate, and an internal standard. The 
mixtures were applied to an Oasis HLB μElution solid-phase extraction plate (Waters), 
and analytes were eluted with 100 μl of methanol. Distilled water (100 μl) was added to 
each elute, and 10-μl aliquots were then subjected to LC-MS/MS. 
For the stomach tissue, the stomach homogenate was further diluted with the same 
volume of distilled water to the homogenate. Thereafter, 10 μl of 50% methanol and 
200 μl of 2% trichloroacetate were added to the solution. Following centrifugation, an 
internal standard was added to 300 μl of supernatant. The solution was applied to an Oasis 
HLB μElution solid-phase extraction plate, and the analytes were eluted with 40 μl 
methanol. Distilled water (40 μl) was added to each elute, and 20-μl aliquots were then 
subjected to LC-MS/MS. 
LC-MS/MS analysis was performed on an API 4000 tandem mass spectrometer 
(ABSciex, Foster City, CA, USA) equipped with a solvent delivery system (LC-30AD) 
and auto-injector (SIL-30AC; both from Shimadzu, Kyoto, Japan) using a reverse phase 
column (CAPCELL PAK C18 MGII; Shiseido, Tokyo, Japan). Electrospray ionization was 
performed in the positive-ion mode. Acotiamide and an internal standard were quantified 
using the selected reaction-monitoring mode with a flow rate of 0.8 ml/min methanol/20 
mM ammonium acetate (pH6.0) (6:4). The monitoring ions for acotiamide and the internal 
standard were m/z 451 → m/z 271 and m/z 465 → m/z 364, respectively. 
5.2.7. Quantification of ACh by LC-MS/MS  
For the quantification of ACh, 20 μl of stomach homogenate sample was mixed with 
100 μl of acetonitrile, and 10 μl of internal standard was then added to the resulting 
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solution. After centrifugation for 10 min (16,000 × g), the supernatant was collected and 
subjected to LC-MS/MS.  
LC-MS/MS analysis was performed on an API 4000 tandem mass spectrometer with a 
solvent delivery system (LC-30AD) and auto-injector (SIL-30AC) using a HILIC column 
(Atlantis
®
 HILIC; Waters). Electrospray ionization was performed in positive-ion mode. 
ACh and an internal standard were quantified using the selected reaction-monitoring mode 
at a flow rate of 0.3 ml/min acetonitrile/10 mM ammonium formate (pH 3.0) (65:35). The 
monitoring ions for acetylcholine and the internal standard were m/z 146 → m/z 87 and 
m/z 155 → m/z 87, respectively. 
5.2.8. PBPK/PD model  
All plasma concentration data were converted to blood concentration data using 
Equation 2-1, as follows: 
bppa RCC   ······································································ 2-1 
where Ca, Cp, and Rbp denote the arterial blood concentration, plasma concentration, 
and blood-to-plasma concentration ratio (Rbp=0.84), respectively. 
The blood concentrations of acotiamide were fitted to Equation 2-2, as follows: 
 ·································· 2-2 
The tissue concentrations of acotiamide were analyzed by the model shown in Fig. 
3-1.  
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Fig. 3-1.  Physiologically-based pharmacokinetic and pharmacodynamic model to describe the 
distribution of acotiamide and AChE inhibition in rat stomach following intravenous administration 
All terms and mass balance for the model are described in “Materials and Methods”. 
 
The mass balance equations of each compartment are as follows: 
Vascular space: 
 ··························· 2-3 
Precursor pool: 
 ············· 2-4 
Deep pool: 
 ·············································· 2-5 
Vd, Vstomach and Cstomach are defined by the following equations: 
 ······································································· 2-6 
 ···································································· 2-7 
 ·································································· 2-8 
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where AT and Ad denote the amounts of acotiamide in the precursor and deep pools, 
respectively; C1, Ce, CT, and Cd denote the acotiamide concentrations in the arterial blood, 
vascular space, precursor pool, and deep pool, respectively; and Ve, VT, and Vd denote the 
volumes of the vascular space, precursor pool, and deep pool, respectively. Qt and Vstomach 
represent blood flow rate and stomach tissue volume, respectively. fb∙PSinf and fu∙PSeff are 
the permeation clearances for the influx and efflux of acotiamide between the vascular 
space and precursor pool, respectively. The deep pool operates under linear conditions and 
can be characterized by first-order rate constants (kass and kdis). Ve can be described as the 
product of Vi and tissue weight [33]. Data fitting of the model equations was performed 
using the Phoenix model of the WinNonlin version 6.1 (Pharsight Corp., Mountain View, 
CA, USA). 
ACh concentration in the stomach was simulated using the following model. A 
pharmacodynamic (PD) model was used as Model 2 [43, 44], and integrated into the 
PBPK model to estimate the stomach distribution of ACh. According to Model 2, the rate 
of change in drug response can be described as follows: 
 ················································ 2-9 
where kin is the zero-order constant for the production of ACh, and kout defines the 
first-order rate constant of hydrolysis of ACh by AChE. R is the observed concentration of 
ACh, and IC50 is the acotiamide concentration that produces 50% maximal effect. Data 
fitting of the model equations was performed using the Phoenix model of the WinNonlin 
version 6.1. 
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5.3. Results 
5.3.1. PBPK modeling 
Upon modeling of the disposition of acotiamide in rats, the blood and stomach 
concentrations of acotiamide were determined after the intravenous administration of 
acotiamide to rats (Fig. 3-2). The gastric concentration of acotiamide in the first two 
sampling point was approximately equal, suggesting the involvement of the 
time-consuming process in the distribution of acotiamide into the stomach. The 
assumption was supported by the result of integration plot analysis in the report, which 
showed that the distribution of acotiamide in the stomach consisted of both rapid and slow 
equilibrium with the blood [20]. We therefore assumed that the vascular space was 
involved in rapid equilibrium with the blood and the extravascular compartment was 
involved in slow equilibrium with the blood (Fig. 3-1). Moreover, the blood-flow 
independent membrane permeability clearance (fb∙PSinf) reported in the report [20], which 
suggested that carrier mediated uptake process was involved in the distribution of 
acotiamide to the stomach, was applied to the distribution process of acotiamide into the 
stomach. After the distribution process, acotiamide was eliminated from the blood and 
stomach in a biexponential manner (Fig. 3-2). Acotiamide in the stomach was slowly 
eliminated compared with the blood compartment (Fig. 3-2). We assumed the precursor 
pool where acotiamide is unbound and the deep pool where acotiamide nonspecifically 
interacts with cellular components (Fig. 3-1). Overall, acotiamide is first distributed into 
the vascular space, and subsequently transported from the vascular space to the precursor 
pool in the PBPK model. 
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5.3.2. Analysis of blood and stomach concentrations of acotiamide 
The blood and stomach concentrations were fitted to a PBPK model describing the 
time course of acotiamide concentration in the blood and stomach (Fig. 3-2). The 
concentration of acotiamide in the precursor pool of stomach decreased to approximately 2 
µM at 2 h after administration. The concentration of acotiamide in the deep pool of 
stomach was estimated below 0.01 µM after the administration of acotiamide. The 
terminal phase for the stomach concentration was well fitted by the deep pool of stomach. 
The kinetic parameters for acotiamide are summarized in Table 3-1. The fitting quality or 
suitability of the PBPK model was assessed using the maximized log-likelihood function 
(Loglik) and Akaike’s information criterion (AIC), which indicated that the developed 
PBPK model is appropriate for describing the kinetics of acotiamide (Fig. 3-2 and Table 
3-2). 
 
Fig. 3-2.  Profiles and model simulations of acotiamide concentrations in the blood, stomach, 
precursor pool, and deep pool after intravenous administration to rats. 
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Each point and vertical bar represents the mean ± S.E. of six rats. All values of S.E. are inside the 
symbols. Open and closed circles indicate blood concentration and stomach concentration, respectively. 
Solid, dotted, dashed, and dashed-dotted lines represent the time course of acotiamide concentration in 
the blood, stomach, precursor pool, and deep pool, respectively. Symbols represent experimentally 
observed concentrations; lines are simulated concentration profiles using the PBPK model from Fig. 
3-1. 
 
Table 3-1.  Physiological and pharmacokinetic parameters for PBPK analysis in rats 
Parameter Value Source 
V1 (ml/kg) 302 By fitting 
k1 (min
-1
) 0.126 By fitting 
k2 (min
-1
) 0.0313 By fitting 
CLtot (ml/min/kg) 56.9 By fitting 
Ve (ml) 0.441 
Calculated from Vi [20] and tissue 
weight [33] 
Vstomach (ml) 1.1 Hosseini-Yeganeh and McLachlan [33] 
fb·PSinf (ml/min) 0.174 Yoshii et al., 2011 [20] 
Qt (ml/min) 1.1 Hosseini-Yeganeh and McLachlan [33] 
VT (ml) 0.133 By fitting 
fu·PSeff (ml/min) 0.00600 By fitting 
kass (min
-1
) 0.0000320 By fitting 
kdis (min
-1
) 0.00000485 By fitting 
IC50 (μM) 1.79 In vitro study 
kin (nmol/g of tissue/min) 0.00314 By fitting 
kout (min
-1
) 0.00415 By fitting 
 
Table 3-2.  Fitting quality of the PBPK model for the time course of acotiamide 
concentrations in blood and stomach 
Loglik AIC 
36.0 −61.9 
Loglik, maximized log-likelihood function; AIC, Akaike’s information criterion 
Calculated using number of observations=26 and number of parameters=5 
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5.3.3. Inhibition of the hydrolysis of MATP+ by acotiamide  
The effect of acotiamide on AChE derived from rat stomach is shown in Fig. 3-3. The 
hydrolysis velocity of MATP+ decreased with increasing acotiamide concentration, with 
an IC50 value of 1.79 µM (Table 3-1). 
 
Fig. 3-3.  Inhibition of MATP+ hydrolysis by acotiamide. 
Each point and vertical bar showing the hydrolysis velocity (v0) of MATP+ represents the mean ± S.E. 
for three determinations. 
5.3.4. PD modeling 
The indirect response model was linked with the PBPK model for describing the 
inhibition of AChE by acotiamide. The concentration of acotiamide used in the PD model 
was chosen as the concentration of acotiamide in the precursor pool of stomach, which 
covered the IC50 value for the inhibition of AChE by acotiamide.  
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5.3.5. Analysis of stomach concentration of ACh   
The profile of ACh after the administration of acotiamide is shown in Fig. 3-4. The 
concentration of ACh rose to 131% (% of baseline) at 2 h after administration of 
acotiamide. When the data of ACh concentrations was fitted to the PBPK/PD model 
without fixing the PD parameters (kin, kout and IC50), kin, kout and IC50 were 
0.00337 nmol/g of tissue/min, 0.00446 min
-1
 and 2.10 µM, respectively. At that fitting, 
Loglik and AIC were 43.9 and -75.8, respectively, which indicated that the PBPK/PD 
model is appropriate for describing the kinetics of ACh. When the data of ACh 
concentrations was fitted to the model with fixing IC50 (1.79 µM), the profile of stomach 
concentration of ACh was well estimated by the PBPK/PD model on the assumption that 
acotiamide in the precursor pool of stomach inhibited AChE (Fig. 3-4). 
 
Fig. 3-4.  Profile and model simulation of ACh concentration in the stomach homogenate after 
intravenous administration of acotiamide to rats. 
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Each point and vertical bar represents the mean ± S.E. of six rats. Symbols represent experimentally 
observed concentrations, while curves show the simulated concentration profiles from the PBPK/PD 
model (Fig. 3-1). 
5.4. Discussion 
The stomach concentration of acotiamide was higher than the blood concentration in 
the first time point when acotiamide concentration was measured after intravenous 
administration of acotiamide to rats. Acotiamide was slowly eliminated in the stomach 
compared to the blood. The PBPK model well described the profile of acotiamide 
concentration in the blood and stomach in the assumption that acotiamide was rapidly 
distributed into the vascular space, uptaken to the precursor pool of stomach by carrier 
mediated process and permeated in the deep pool of stomach. ACh, which was determined 
as the marker of the involvement of acotiamide in inhibiting AChE, reached the maximum 
concentration in the stomach at 2 h after intravenous administration of acotiamide, while 
the stomach concentration of acotiamide peaked at 0.0833 h, indicating the existence of 
time lag between the stomach concentration of acotiamide and ACh. The unbound 
concentration of acotiamide in the precursor pool was higher than the in vitro IC50 value of 
acotiamide for inhibiting AChE activity by approximately 2 h after administration of 
acotiamide. The PD model well described the profile of ACh concentration in the stomach 
in the assumption that the unbound concentration of acotiamide in the precursor pool 
inhibited AChE with the in vitro IC50 for AChE inhibition. These results suggested that 
acotiamide inhibited AChE in the precursor pool of stomach where acotiamide was 
distributed by carrier mediated process. 
No reports have been published on a PK model for the distribution of drugs from 
blood to stomach as the pharmacological target although some reports have been reported 
on a PK model containing stomach as delivery organ of drugs to small intestine [45,46,47]. 
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The precursor and deep pool of stomach were put in the model to describe the 
rate-limiting step in the uptake of acotiamide by stomach and slower elimination of 
acotiamide from stomach than blood. Acotiamide in the precursor pool of stomach plays 
an important role in the elevation of ACh in the stomach though the anatomical meanings 
of these compartments remain unclear. It’s normally difficult to estimate the 
microenvironmental concentration of drugs in tissue. For brain, microdialysis method was 
applied to estimate the unbound concentration of drugs penetrating into brain [48,49]. The 
method for prediction of the unbound concentration of drugs in brain was also reported by 
Fridén et al [50]. For stomach, the application of microdialysis to submucosa which is 
thicker than muscular layer and unrelated with gastric motility in the gastric layers was 
only reported [51,52]. Moreover, there is no report concerning the method for prediction 
of the unbound concentration of drugs in stomach. Thus, we proposed a mechanism based 
PK model to estimate the concentration of drugs exerting their pharmacological effects in 
tissues like gastroprokinetic agents in stomach. 
The selectivity of drug to its target is achieved by the specific affinity to drug targets, 
the selective access to site where drug targets exist, and/or the unique localization of drug 
target. For example, histamine H2 receptor, which is only involved in the regulation of 
gastric acid secretion among four subtypes of histamine H receptor, is a selective target for 
the suppressor of gastric acid secretion [53,54]. L-type amino acid transporter 1 is 
consider as a specific target for antitumor because L-type amino acid transporter 1, 
transporting amino acids needed for the growth of cancer cells, selectively expresses in 
cancer cells [55,56]. AChE, the target of acotiamide is a ubiquitous enzyme. In addition, 
ACh which is regulated by AChE interacts with each subtype of muscarinic receptor. 
There might be no selectivity on the pathway from the contact of acotiamide with AChE 
to the evoking of pharmacological action, so the selectivity of acotiamide to its target 
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might be derived only from the feature in the distribution of acotiamide. Thus, it’s seems 
important to put in the distribution parameters to stomach in the development of the 
PBPK/PD model. fb∙PSinf of the distribution parameters was calculated from the uptake 
clearance of acotiamide to stomach [20]. The uptake clearance can be expressed as the 
slope in the integration plot, where stomach to blood concentration ratio is plotted against 
area under the blood concentration curve to blood concentration ratio when the uptake of 
acotiamide was determined in a short time, during which the efflux and/or elimination of 
acotiamide from stomach were negligible. Ve of the distribution parameters (0.401 ml/g of 
tissue) was calculated as the product of the intercept (Vi) of y axis of integration plot and 
tissue weight (Vi ∙ tissue weight). When Ve was compared with the volume of capillary 
bed (0.0108 ml/g of tissue) [57] and inulin space (0.295 ml/g of tissue) [20], Ve was 
similar to inulin space, an extracellular space. Therefore, fb∙PSinf might represent the 
transport of acotiamide through plasma membrane of gastric cells. Moreover, the volume 
of precursor pool (VT) which was 12.1% of the volume of stomach (Vstomach) was similar 
to fraction of acotiamide distributed to the stomach cytosol (12.0%) reported in previous 
report [20]. The result suggested that the volume of precursor and deep pool reflected 
fraction of acotiamide distributed to cytosol and organelle of gastric cells, respectively. 
The time lag between drug concentration and the effect was often observed [43,44,58]. 
For describing the delay of drug effect, the PD models like hypothetical effect 
compartment model and indirect response model were used. The hypothetical effect 
compartment model is useful in the case that mechanism of the delay for drug effect is 
unknown, while the indirect response model is available for drugs whose mechanism of 
the delay is derived from the mechanism of action. An indirect response model was 
chosen as the PD model because acotiamide is a known AChE inhibitor. Dayneka et al. 
classified the indirect response model into four models types-based on the mechanism of 
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action [43]. Based on this classification, the effects of reversible anticholinesterase agents, 
which inhibit the enzymatic breakdown of ACh, demonstrated that the model could be 
categorized as Model 2. The rate of change in drug response using this model is described 
by Equation 2-9, and many drugs described in this manner show a delay compared to the 
time course of the drug concentration. Jusko et al. used an indirect response model to 
describe the muscular response as ACh level in patients with myasthenia gravis during 
therapy using pyridostigmine, acetylcholinesterase inhibitor [59]. Therefore, the indirect 
response model is suitable for describing the inhibitory effect of acotiamide on AChE in 
rat stomach. 
Normally, acetylthiocholine (ATCh) is used to evaluate AChE activity [60]. However, 
ATCh is a known substrate of both AChE and butyrylcholinesterase (BChE), meaning 
BChE inhibitors such as iso-OMPA need to be included in the incubation medium when 
investigating acotiamide effects [15]. Recently, Kikuchi et al. reported that MATP+ was 
suitable AChE selective substrates for detecting of AChE activity [42]. Therefore, in this 
study, we used MATP+ as substrate of AChE for investigation of the effects of acotiamide 
on the AChE activity. Hydrolysis velocity of MATP+ was decreased by the addition of 
acotiamide, with the IC50 value of 1.79 µM.  Kawachi et al. have reported that 
acotiamide inhibited ATCh hydrolysis by stomach homogenate with IC50 value of 2.3 µM 
[17]. Furthermore, acotiamide also inhibited human AChE with Ki value of 0.61 µM [15]. 
The observation was similar to these previously results, therefore, it was considered that 
using of MATP+ for investigation of AChE inhibition is appropriate. 
In conclusion, we elucidated the relationship of the blood and stomach concentration 
of acotiamide with the pharmacological action. Acotiamide was distributed by carrier 
mediated process and inhibited AChE in the precursor pool of stomach. Acotiamide in the 
precursor pool plays an important role for producing the pharmacologic action. Moreover, 
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we proposed PBPK/PD model to describe the pharmacologic action of acotiamide in 
stomach.  
5.5. Summary 
Acotiamide, a gastroprokinetic agent used to treat FD, is transported to at least two 
compartments in rat stomach. However, the role of these stomach compartments in 
pharmacokinetics and pharmacodynamics of acotiamide remains unclear. Thus, the 
purpose of this study was to elucidate the relationship of the blood and stomach 
concentration of acotiamide with its inhibitory effect on AChE. 
Concentration profiles of acotiamide and ACh were determined after intravenous 
administration to rats and analyzed by PBPK/PD model containing vascular space, 
precursor pool and deep pool of stomach. 
Acotiamide was eliminated from the blood and stomach in a biexponential manner. The 
PBPK/PD model estimated that acotiamide concentration in the precursor pool exceeded 
2 µM at approximately 2 h after administration. Acotiamide inhibited AChE activity in 
vitro with a 50% inhibitory concentration of 1.79 µM. ACh reached the maximum 
concentration at 2 h after administration. 
The PBPK/PD model well described the profile of acotiamide and ACh concentration in 
the stomach in the assumption that acotiamide was distributed by carrier mediated process 
and inhibited AChE in the precursor pool of stomach. Thus, Acotiamide in the precursor 
pool plays an important role for producing the pharmacological action. 
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6. Conclusion 
Acotiamide is an AChE inhibitor and gastroprokinetic agent. There is no report for the 
severe adverse effects like cholinergic crisis and fasciculation by inhibition of cholinergic 
nerves in brain and skeletal muscle, so acotiamide might have selectivity for stomach. 
AChE is ubiquitously located in organs other than stomach. The selectivity of acotiamide 
to stomach may be derived from the selective distribution of acotiamide to stomach. The 
distribution of acotiamide to stomach and other organs is related with the pharmacological 
and adverse effect of acotiamide, respectively. Therefore, studies on the distribution of 
acotiamide are important to understand the pharmacological and adverse effects of 
acotiamide. To elucidate the distribution of acotiamide to tissues/organs, the following 
studies were performed. 
To examine whether the concentration of acotiamide at the site of action is sufficient to 
inhibit AChE, the distribution of [
14
C]acotiamide around nerve cells in the myenteric 
plexus of rat and dog stomachs. AChE activity staining showed that AChE as target of 
acotiamide was located around nerve cells in the myenteric plexus of rat and dog stomachs. 
The macro-autoradiography showed the concentration of radioactivity was 27.9 μM in rat 
stomach, which was 12 times higher than IC50 of acotiamide for rat AChE. Being different 
from rats, the distribution of radioactivity in the muscular layer was distinguishable from 
that in the mucosal layer in dog stomach. The concentration of radioactivity in the 
muscular layer of dog stomach (1.41 μM) was approximately two-times lower than those 
in the mucosal layer, however, it was approximately 1.2 times higher than IC50 of 
acotiamide for dog AChE. The results of micro-autoradiography also showed the 
radioactivity distributed homogenously in the muscular layer of rat stomach, suggesting 
the concentration of radioactivity around the ganglion of myenteric plexus is similar to that 
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in the muscular layer of stomach. These findings suggest acotiamide distributes to the 
myenteric plexus of stomach, a putative site of acotiamide action, with adequate 
concentrations to inhibit AChE, in both of rat and dog stomachs. 
To reveal the mechanism of distribution of acotiamide from blood to stomach, the tissue 
distribution of acotiamide was investigated in rats. The tissue-to-plasma concentration 
ratio (Kp,app,in vivo) for stomach decreased from 4.1 to 2.4 ml/g of tissue at steady state with 
increasing plasma concentrations, whereas the Kp,app,in vivo for skeletal muscle was much 
lower and constant regardless of the concentration of acotiamide in plasma. In vitro 
binding to stomach tissue protein exhibited a linear profile, with a predicted Kp,app,in vitro of 
2.2 from free fractions under linear conditions. Therefore, protein binding to stomach 
tissue might only play a limited role in the stomach distribution of acotiamide. The influx 
permeability (fu,b·PSinf,app) in the stomach exhibited dose-dependent saturation at the 
lowest range of examined blood unbound concentrations of acotiamide, whereas that in 
skeletal muscle exhibited only minimal dose dependence. In addition, the unbound 
concentration ratio of stomach to plasma (2.8) at steady state was markedly higher than 
unity. Taken together, these results suggest that carrier-mediated concentrative uptake 
processes play an important role in the distribution of acotiamide to the stomach, but not 
skeletal muscle. 
To elucidate a role of carrier-mediated concentrative uptake process on the 
pharmacokinetics and pharmacodynamics of acotiamide, concentration profiles of 
acotiamide and ACh were determined after intravenous administration to rats and 
analyzed by PBPK/PD model. The PBPK/PD model was developed in the assumption that 
acotiamide was distributed by carrier mediated process and increase ACh via inhibition of 
AChE. Since acotiamide was eliminated from the blood and stomach in a biexponential 
manner, compartments equilibrated rapidly and slowly with blood were set to the 
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PBPK/PD model. As the elimination of acotiamide from stomach was slower than that 
from blood, the precursor and deep pool of stomach was built in PBPK/PD model. The 
PBPK/PD model estimated that acotiamide concentration in the precursor pool exceeded 
2 µM at approximately 2 h after administration. Acotiamide inhibited AChE activity in 
vitro with IC50 of 1.79 µM. ACh reached the maximum concentration at 2 h after 
administration. The PBPK/PD model well described the profile of acotiamide and ACh 
concentration in the stomach. Thus, the carrier-mediated concentrative uptake process 
plays an important role for pharmacokinetics and pharmacodynamics of acotiamide. 
These studies suggest that acotiamide is distributed via carrier-mediated concentrative 
uptake process to stomach, inhibits AChE around nerve cells in the myenteric plexus of 
stomach, and increases ACh involving gastric motility, while acotiamide is hardly ever 
distributed to brain and skeletal muscle. Therefore, acotiamide has effectiveness and safety 
for the treatment of FD. 
Further studies are needed for the identification of transporter involved in the 
carrier-mediated concentrative uptake process of acotiamide to stomach. 
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